Which peptides have been tested in people
Of the 25 compounds, 20 have at least one clinical trial about them in PubMed and 5 have none: BPC-157, IGF-1 LR3, KPV, AOD-9604 and Dihexa. The most tested are Glutathione (481), NAD+ (62) and Kisspeptin-10 (49). Counted again every day from the two registries; nothing here is a claim that a compound works.
| Compound | Clinical trials about it | Randomized | Reviews | Papers naming it | In animals only | Registered studies | Reports to the FDA |
|---|---|---|---|---|---|---|---|
| Glutathione | 481 | 264 | 246 | 33,778 | 12,652 (37%) | 61 (38 done) | 2,648 |
| NAD+ | 62 | 30 | 28 | 10,899 | 3,555 (33%) | 18 (8 done) | 51 |
| Kisspeptin-10 | 49 | 26 | 15 | 3,346 | 1,680 (50%) | 24 (15 done) | 1 |
| VIP peptide | 43 | 19 | 1 | 2,804 | 1,666 (59%) | 16 (11 done) | 30 |
| Thymosin alpha-1 | 39 | 27 | 7 | 632 | 185 (29%) | 40 (16 done) | 251 |
| LL-37 | 17 | 9 | 0 | 3,041 | 216 (7%) | 8 (7 done) | 0 |
| SS-31 | 15 | 14 | 0 | 586 | 213 (36%) | 22 (14 done) | 3 |
| PT-141 | 15 | 14 | 2 | 114 | 7 (6%) | 10 (9 done) | 1,151 |
| Tesamorelin | 15 | 14 | 2 | 107 | 3 (3%) | 20 (10 done) | 3,625 |
| DSIP | 12 | 5 | 0 | 407 | 287 (71%) | 0 | 0 |
| Sermorelin | 9 | 5 | 0 | 370 | 133 (36%) | 0 | 69 |
| ARA-290 | 5 | 4 | 0 | 77 | 27 (35%) | 2 (1 done) | 0 |
| Semax | 4 | 1 | 0 | 210 | 145 (69%) | 0 | 2 |
| MOTS-c | 3 | 3 | 0 | 266 | 54 (20%) | 2 | 0 |
| Selank | 3 | 2 | 0 | 68 | 49 (72%) | 0 | 0 |
| Ipamorelin | 2 | 2 | 0 | 51 | 20 (39%) | 2 (2 done) | 13 |
| Epitalon | 2 | 1 | 0 | 166 | 103 (62%) | 0 | 0 |
| CJC-1295 | 2 | 1 | 0 | 36 | 5 (14%) | 1 | 5 |
| TB-500 | 1 | 1 | 0 | 633 | 216 (34%) | 10 (4 done) | 5 |
| GHK-Cu | 1 | 1 | 0 | 149 | 18 (12%) | 1 | 2 |
| BPC-157 | 0 | 0 | 1 | 230 | 104 (45%) | 2 | 24 |
| IGF-1 LR3 | 0 | 0 | 0 | 100 | 68 (68%) | 0 | 0 |
| KPV | 0 | 0 | 0 | 45 | 13 (29%) | 0 | 0 |
| AOD-9604 | 0 | 0 | 0 | 23 | 3 (13%) | 0 | 0 |
| Dihexa | 0 | 0 | 0 | 18 | 4 (22%) | 0 | 0 |
Counted from PubMed (pubmed.ncbi.nlm.nih.gov) and ClinicalTrials.gov (clinicaltrials.gov) on 16 November 2026, and again every day. A clinical trial, randomized trial or review counts when the compound is in its title (for a molecule the body makes, such as NAD+, glutathione or VIP, that includes trials that only measure it); papers are counted by the compound in the title or abstract, or in the title alone for those three; “in animals only” is PubMed's own indexing of a paper as about animals and not people; a registered study counts when its listed interventions name the compound. Reports to the FDA are FAERS reports naming the compound (openFDA): what was reported, never proof of cause and never a rate. Ordered by clinical trials, then randomized trials. Each compound's page lists its newest studies and the exact searches.
The same figures as a file: peptide-research.csv, one row per compound with the exact PubMed searches.
The newest trials and reviews, across compounds
Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis
Glutathione · Systematic review · Basic Clin Pharmacol Toxicol · 1 November 2026 · PMID 42876024
Hyaluronic acid-based skin booster with glutathione combined with 1064-nm Nd:YAG laser and oral tranexamic acid for melasma: A prospective comparative study
Glutathione · Randomized trial · Medicine (Baltimore) · 16 October 2026 · PMID 42888572
Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety
BPC-157 · Systematic review · Acta Orthop Belg · 8 October 2026 · PMID 42885452
Glutathione in redox homeostasis: Bridging molecular mechanisms, bioavailability constraints, and translational challenges in systemic therapeutics
Glutathione · Systematic review · Biomed Pharmacother · 1 October 2026 · PMID 42585816
Extender-dependent effects of reduced glutathione on post-thaw boar sperm quality: A systematic review and meta-analysis
Glutathione · Meta-analysis · Anim Reprod Sci · 1 October 2026 · PMID 42413192
NAD(+) signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
NAD+ · Systematic review · Front Neurol · 30 September 2026 · PMID 42877680
Domain-specific effects of NAD(+) precursors on fatigue and functional performance: a systematic review and network meta-analysis
NAD+ · Systematic review · Front Nutr · 8 September 2026 · PMID 42774067
Formulation-dependent differences in systemic glutathione availability: Comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults
Glutathione · Randomized trial · Eur J Pharm Biopharm · 1 September 2026 · PMID 42392376
Vasoactive intestinal Peptide as a diagnostic or prognostic biomarker in multiple sclerosis: A systematic review
VIP peptide · Systematic review · Mult Scler Relat Disord · 1 September 2026 · PMID 42447728
Neurotransmitter and neuromodulator imbalance in kisspeptin/GnRH regulation in rodent models of polycystic ovary syndrome and its implications for mental health disorders: A systematic review
Kisspeptin-10 · Systematic review · Behav Brain Res · 5 August 2026 · PMID 42140496
Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men
Kisspeptin-10 · Randomized trial · Eur J Endocrinol · 3 August 2026 · PMID 42549827
Integrative functional bioinformatic analysis of NAD(+)-associated protein coding genes in adipose tissue (dys)function - evidence from targeted rodent transcriptomic studies
NAD+ · Systematic review · Front Endocrinol (Lausanne) · 21 July 2026 · PMID 42553099
Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial
NAD+ · Randomized trial · Geroscience · 1 June 2026 · PMID 41162813
NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis
NAD+ · Randomized trial · JCI Insight · 28 April 2026 · PMID 42048163
Serum kisspeptin levels in women with polycystic ovary syndrome: A systematic review and meta-analysis
Kisspeptin-10 · Meta-analysis · Med J Malaysia · 1 March 2026 · PMID 41914593
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial
Thymosin alpha-1 · Clinical trial · BMC Med · 26 February 2026 · PMID 41749205
Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans
Kisspeptin-10 · Clinical trial · J Neuroendocrinol · 1 January 2026 · PMID 41273106
Associations between kisspeptin hormone level and its genetic polymorphisms with polycystic ovary syndrome
Kisspeptin-10 · Meta-analysis · Int J Gynaecol Obstet · 1 January 2026 · PMID 40704698
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis
Tesamorelin · Meta-analysis · J Int Assoc Provid AIDS Care · 1 January 2026 · PMID 42538058
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Tesamorelin · Meta-analysis · Obes Res Clin Pract · 1 January 2026 · PMID 41545261
Registered studies updated most recently
A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults
NAD+ · NCT07692633 · recruiting · 80 people · updated 13 November 2026
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
TB-500 · NCT07487363 · recruiting · Phase 1, Phase 2 · 80 people · updated 12 November 2026
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease
Tesamorelin · NCT07481734 · recruiting · Phase 2 · 120 people · updated 12 November 2026
Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome
SS-31 · NCT07927972 · not yet recruiting · Phase 1 · 6 people · updated 10 November 2026
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
SS-31 · NCT07531251 · recruiting · Phase 4 · 48 people · updated 9 November 2026
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Tesamorelin · NCT03150511 · recruiting · Phase 2 · 36 people · updated 9 November 2026
Thymosin Alpha 1 and IgM Levels in Sepsis
Thymosin alpha-1 · NCT07922954 · active, not recruiting · Phase 4 · 36 people · updated 6 November 2026
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
LL-37 · NCT07280754 · recruiting · 72 people · updated 3 November 2026
Combination Gerotherapeutic Interventions for Healthspan Improvement
NAD+ · NCT07475546 · completed · Phase 3 · 26 people · updated 30 October 2026
An Intermediate Size Expanded Access Protocol of Elamipretide
SS-31 · NCT04689360 · expanded access available · updated 27 October 2026
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
Thymosin alpha-1 · NCT07884201 · not yet recruiting · Phase 2 · 572 people · updated 20 October 2026
Prevent Cardiac Surgery Associated AKI Trial
Glutathione · NCT06620523 · recruiting · Phase 2 · 242 people · updated 14 October 2026
Thymalfasin for Immune Recovery in Adults With Sepsis
Thymosin alpha-1 · NCT07866118 · recruiting · 60 people · updated 8 October 2026
Comparison of Three Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
NAD+ · NCT07132801 · completed · 76 people · updated 6 October 2026
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
NAD+ · NCT06505967 · completed · 170 people · updated 5 October 2026
About the research
Which peptides have been tested in people?
Of the 25 compounds, 20 have at least one clinical trial about them in PubMed and 5 have none: BPC-157, IGF-1 LR3, KPV, AOD-9604 and Dihexa. The most tested are Glutathione (481), NAD+ (62) and Kisspeptin-10 (49).
Which peptides have no clinical trials?
By PubMed's count of clinical trials with the compound in the title: BPC-157 (230 papers, 104 in animals only), IGF-1 LR3 (100 papers, 68 in animals only), KPV (45 papers, 13 in animals only), AOD-9604 (23 papers, 3 in animals only), Dihexa (18 papers, 4 in animals only), counted 16 November 2026.
Does a clinical trial mean a peptide works?
No. A count says how much of the research is in people, not what it found: a trial can be small, early, negative or never published. Each compound's page names its newest trials and reviews so you can read them.